香港股市 將在 2 小時 20 分鐘 開市

GSK plc (GSK)

NYSE - NYSE 延遲價格。貨幣為 USD。
加入追蹤清單
39.75+0.48 (+1.22%)
收市:04:00PM EDT
39.71 -0.04 (-0.10%)
收市後: 07:52PM EDT
全螢幕
交易股價資料並非來自所有市場
前收市價39.27
開市39.37
買盤39.31 x 1000
賣出價40.15 x 1400
今日波幅39.37 - 39.76
52 週波幅33.33 - 43.84
成交量1,623,882
平均成交量3,557,149
市值81.21B
Beta 值 (5 年,每月)0.27
市盈率 (最近 12 個月)13.29
每股盈利 (最近 12 個月)2.99
業績公佈日
遠期股息及收益率1.47 (3.69%)
除息日2024年2月22日
1 年預測目標價45.32
  • Insider Monkey

    10 Best Weight Loss Drug Stocks to Buy Now

    In this piece, we will take a look at the ten best weight loss drug stocks to buy now. If you want to skip our introduction to the rising weight loss drug industry and how it’s one of the biggest trends on the stock market right now, then you can take a look at the […]

  • Zacks

    GSK PLC Sponsored ADR (GSK) is Attracting Investor Attention: Here is What You Should Know

    Recently, Zacks.com users have been paying close attention to Glaxo (GSK). This makes it worthwhile to examine what the stock has in store.

  • Reuters

    UPDATE 1-U.S. FDA approves Akebia's anemia drug

    The U.S. Food and Drug Administration approved Akebia Therapeutics' drug, vadadustat, to treat anemia caused by chronic kidney disease (CKD) in dialysis patients, the drugmaker said on Wednesday. The FDA had earlier declined to approve vadadustat - a Hypoxia-inducible factor–prolyl hydroxylase (HIF-PH) inhibitor - on safety concerns, as it posed an increased risk of blood clot formations and drug-induced injuries to the liver.